Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,336 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: COVID-19 Infection Clear all
Terminated Not applicable Interventional

Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting

NCT06113679
View directory record Official record
Conditions
Post COVID-19 Condition (PCC)
Interventions
RDX-19
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
22 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
East Amherst, New York • Milan, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo

NCT05107479
View directory record Official record
Conditions
COVID-19 Vaccine Knowledge, COVID-19 Vaccine Beliefs
Interventions
COVID-19 Vaccine IVR Training, Control Condition
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8,959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2022 · Synced Sep 17, 2026, 1:48 PM EDT
Withdrawn Phase 2 Interventional

Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela

NCT04905888
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric oxygen therapy
Combination Product
Lead sponsor
Peter Lindholm
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Sep 17, 2026, 1:48 PM EDT
Completed No phase listed Observational

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.

NCT07090486
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir-ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
14,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 17, 2026, 1:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients

NCT04379518
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Recombinant Interferon Alfa-2b, Rintatolimod
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 17, 2026, 1:48 PM EDT
Completed No phase listed Observational

Investigating Immune Escape by SARS-CoV-2 Variants

NCT05171803
View directory record Official record
Conditions
COVID-19; Immunity
Interventions
No intervention
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Dimas, California
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

ACTIV-2: A Study for Outpatients With COVID-19

NCT04518410
View directory record Official record
Conditions
Coronavirus, Covid19
Interventions
bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,044 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
207
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 4 Interventional

COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
Interventions
Upadacitinib, Abatacept, Secukinumab, Tofacitinib, TNF Inhibitor, Canakinumab Injection, Baricitinib, Ixekizumab
Drug
Lead sponsor
Jeffrey Curtis
Other
Eligibility
18 Years to 85 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2020 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Study of Sargramostim in Patients With COVID-19

NCT04411680
View directory record Official record
Conditions
COVID-19, SARS-CoV-2
Interventions
Sargramostim, Standard of care
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Fullerton, California • Orange, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Sep 17, 2026, 1:48 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic

NCT04769297
View directory record Official record
Conditions
Acute Stress Disorder
Interventions
Sublingual Micro-Dose Ketamine
Drug
Lead sponsor
Limbic Medical
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Toluca Lake, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Sep 17, 2026, 1:48 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of SLV213 for the Treatment of COVID-19.

NCT06146374
View directory record Official record
Conditions
COVID-19
Interventions
Placebo for SLV213, SLV213
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 17, 2026, 1:48 PM EDT
Terminated Not applicable Interventional Results available

Inpatient COVID-19 Lollipop Study

NCT05801341
View directory record Official record
Conditions
COVID-19, Diagnostic Test
Interventions
Lollipop
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Duvelisib to Combat COVID-19

NCT04372602
View directory record Official record
Conditions
COVID-19
Interventions
Duvelisib, Peripheral blood draw, Placebo
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 5, 2023 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

NCT04470427
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30,415 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
100
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 17, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

Impact of Lp299v on Vascular Function in Patients With PASC

NCT05227170
View directory record Official record
Conditions
COVID-19
Interventions
Lactobacillus Plantarum 299v Freeze Dried Capsule, Freeze Dried Potato Starch Capsule
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 89 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Pfizer-BioNTech COVID-19 Vaccine 2023-2024, Moderna COVID-19 Vaccine 2023-2024, SOC IS Regimen, SOC IS Reduction
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 17, 2026, 1:48 PM EDT
Completed No phase listed Observational

Evaluation of Antibody Tests for COVID-19

NCT04360954
View directory record Official record
Conditions
COVID, Coronavirus
Interventions
Diagnostic test
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
461 participants
Timeline
2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

NCT05122260
View directory record Official record
Conditions
COVID-19 Prevention
Interventions
Q-Griffithsin, Placebo
Drug · Other
Lead sponsor
Kenneth Palmer
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 17, 2026, 1:48 PM EDT
Withdrawn No phase listed Observational

ImmuneSense™ COVID-19 Cross-Reactivity Study

NCT05112874
View directory record Official record
Conditions
Coronavirus Disease, SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
Adaptive Biotechnologies
Industry
Eligibility
18 Years to 89 Years
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 17, 2026, 1:48 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Citizen Science Expansion Project

NCT05548803
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
52,351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
9
States / cities
Sacramento, California • San Francisco, California • Downers Grove, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 17, 2026, 1:48 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Validation of Biomarkers for Long COVID in the LIINC Viral Immunopathogenesis and Persistence Repeat Donor Cohort (VIPER)

NCT07770022
View directory record Official record
Conditions
Long Covid
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 17, 2026, 1:48 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298
View directory record Official record
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 17, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Optimization of a New Adaptive Intervention to Increase COVID-19 Testing

NCT04757298
View directory record Official record
Conditions
COVID-19 Testing
Interventions
Navigation Services, Critical Dialogue, Brief Counseling, Referral and Digital Brochure
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years and older
Enrollment
668 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 17, 2026, 1:48 PM EDT